The short version of immunomodulator fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
=== Class I === Class I fusion proteins resemble influenzavirus hemagglutinin in their structure. Post-fusion, the active site has a trimer of α-helical coiled-coils. The binding domain is rich in α-helices and hydrophobic fusion peptides located near the N-terminus (some examples show internal fusion peptides, however). Fusion conformation change can often be controlled by pH.
The epidermis is the strong, superficial layer that serves as the first line of protection against the outer environment. The human epidermis is composed of stratified squamous epithelial cells, which further break down into four to five layers: the stratum corneum, stratum granulosum, stratum spinosum and stratum basale. Where the skin is thicker, such as in the palms and soles, there is an extra layer of skin between the stratum corneum and the stratum granulosum called the stratum lucidum. The epidermis is regenerated from the stem cells found in the basal layer that develop into the corneum. The epidermis itself is devoid of blood supply and draws its nutrition from its underlying dermis. Its main functions are protection, absorption of nutrients, and homeostasis. In structure, it consists of a keratinized stratified squamous epithelium; four types of cells: keratinocytes, melanocytes, Merkel cells, and Langerhans cells. The predominant cell keratinocyte, which produces keratin, a fibrous protein that aids in skin protection, is responsible for the formation of the epidermal water barrier by making and secreting lipids. The majority of the skin on the human body is keratinized, with the exception of the lining of mucous membranes, such as the inside of the mouth. Non-keratinized cells allow water to "stay" atop the structure. The protein keratin stiffens epidermal tissue to form fingernails. Nails grow from a thin area called the nail matrix at an average of 1 mm per week.
==== Conductivity/resistivity ==== In ultra-pure water systems, electrolytic conductivity or resistivity, which are reciprocals of each other, is used as a general indicator of water purity. Absolutely pure water has a conductivity of 0.05501 μS/cm and a resistivity of 18.18 MΩ⋅cm at 25 °C, and ultra-pure water is typically specified to approach or meet this target. Resistivity is highly sensitive to contamination by ions, and 0.1 ppb of sodium chloride decreases the resistivity to 18.11 MΩ⋅cm (equivalent to 0.05523 μS/cm). Ultrapure water is easily contaminated by traces of carbon dioxide from the atmosphere passing through tiny leaks or diffusing through thin wall polymer tubing when sample lines are used for measurement. Carbon dioxide forms conductive carbonic acid in water which dissociates into H+ and bicarbonate. For this reason, conductivity probes are often used to provide continuous monitoring of conductivity/resistivity to ensure purity.
Sources: en.wikipedia.org
== Personal life == After raising their 6 children, James, Nancy, Betsy, Cathy, Laurie and Sally, his wife Elizabeth (Libby), a biologist by training, joined the Merrifield laboratory at Rockefeller University where she worked for over 23 years. After a long illness, R. Bruce Merrifield died on May 14, 2006, at the age of 84 in his home in Cresskill, New Jersey. At the time of his death he was survived by his wife Libby, their 6 children and 16 grandchildren. Libby died on September 13, 2017.
Other tyrannosaur fossils found in the same formations as T. rex were originally classified as separate taxa, including Aublysodon and Albertosaurus megagracilis, the latter being named Dinotyrannus megagracilis in 1995. These fossils are now universally considered to belong to juvenile T. rex. A small but nearly complete skull from Montana, 57.2 centimeters (1.88 ft) long, is an exception. This skull, CMNH 7541, was originally classified as a species of Gorgosaurus (G. lancensis) by Charles W. Gilmore in 1946. In 1988, the specimen was re-described by Robert T. Bakker, Michael Williams, then the curator of paleontology at the Cleveland Museum of Natural History, and Phil Currie, where the original specimen was housed and is now on display. Their initial research indicated that the skull bones were fused, and that it therefore represented an adult specimen. In light of this, Bakker and colleagues assigned the skull to a new genus named Nanotyrannus (meaning "dwarf tyrant", for its apparently small adult size). However, in 1999, a detailed analysis by Thomas Carr revealed the specimen to be a juvenile, leading Carr and many other paleontologists to consider it a juvenile T. rex individual.
S2F10 + Cl2 → 2 SF5Cl The analogous reaction with bromine is reversible and yields SF5Br. The reversibility of this reaction can be used to synthesize S2F10 from SF5Br. It reacts with SO2 to form pentafluorosulfur fluorosulfonate (SF5OSO2F) in the presence of ultraviolet radiation. Ammonia is oxidised by S2F10 into NSF3.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.